AC Immune (ACIU) Operating Expenses (2015 - 2026)

AC Immune (ACIU) has 12 years of Operating Expenses data on file, last reported at -$20.3 million in Q1 2026.

• Quarterly Operating Expenses rose 10.3% year-over-year to -$20.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$85.1 million (up 5.58% YoY) and the FY2025 annual result came in at -$87.9 million, up 3.35% from the prior year.
• Operating Expenses slipped to -$20.3 million in Q1 2026 per ACIU's latest filing, from -$18.4 million in the prior quarter.
• Across five years, Operating Expenses topped out at -$17.5 million in Q3 2023 and bottomed at -$25.0 million in Q2 2025.
• The 5-year median for Operating Expenses is -$20.6 million (2022), against an average of -$20.8 million.
• The widest annual swing landed in 2022, when Operating Expenses increased 21.46%; it then retreated 26.27% in 2024.
• Tracing ACIU's Operating Expenses over 5 years: stood at -$19.4 million in 2022, then retreated by 6.54% to -$20.7 million in 2023, then retreated by 9.06% to -$22.6 million in 2024, then advanced by 18.26% to -$18.4 million in 2025, then decreased by 10.21% to -$20.3 million in 2026.
• Per Business Quant, the three latest ACIU Operating Expenses figures stand at -$20.3 million (Q1 2026), -$18.4 million (Q4 2025), and -$21.4 million (Q3 2025).

Peer Comparison